EP4045640 - SYNTHETIC GENES FOR THE TREATMENT OF PROPIONIC ACIDEMIA CAUSED BY MUTATIONS IN PROPIONYL-COA CARBOXYLASE BETA [Right-click to bookmark this link] | Status | Request for examination was made Status updated on 22.07.2022 Database last updated on 03.09.2024 | |
Former | The international publication has been made Status updated on 24.04.2021 | ||
Former | unknown Status updated on 20.11.2020 | Most recent event Tooltip | 28.10.2023 | New entry: Renewal fee paid | Applicant(s) | For all designated states The United States of America, as represented by the Secretary, Department of Health and Human Services Office of Technology Transfer National Institutes of Health 6701 Rockledge Drive, Suite 700 MSC 7788, Bethesda Maryland 20892-7788 / US | [2022/34] | Inventor(s) | 01 /
VENDITTI, Charles P. 13001 Boswell Court Potomac, Maryland 20854 / US | 02 /
CHANDLER, Randy J. 3203 Winnett Road Chevy Chase, Maryland 20815 / US | [2022/34] | Representative(s) | Vossius & Partner Patentanwälte Rechtsanwälte mbB Siebertstraße 3 81675 München / DE | [2022/34] | Application number, filing date | 20804709.2 | 15.10.2020 | [2022/34] | WO2020US55836 | Priority number, date | US201962915347P | 15.10.2019 Original published format: US 201962915347 P | [2022/34] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2021076797 | Date: | 22.04.2021 | Language: | EN | [2021/16] | Type: | A1 Application with search report | No.: | EP4045640 | Date: | 24.08.2022 | Language: | EN | The application published by WIPO in one of the EPO official languages on 22.04.2021 takes the place of the publication of the European patent application. | [2022/34] | Search report(s) | International search report - published on: | EP | 22.04.2021 | Classification | IPC: | C12N9/00, C12N15/86 | [2022/34] | CPC: |
C12N9/93 (EP,US);
C12N15/86 (EP,US);
C12Y604/01003 (EP,US);
A61K48/00 (US);
C12N2750/14143 (EP,US);
C12N2800/22 (EP,US);
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2022/34] | Title | German: | SYNTHETISCHE GENE FÜR DIE BEHANDLUNG VON DURCH MUTATIONEN IN PROPIONYL-COA-CARBOXYLASE-BETA VERURSACHTE PROPIONSÄUREÄMIE | [2022/34] | English: | SYNTHETIC GENES FOR THE TREATMENT OF PROPIONIC ACIDEMIA CAUSED BY MUTATIONS IN PROPIONYL-COA CARBOXYLASE BETA | [2022/34] | French: | GÈNES SYNTHÉTIQUES POUR LE TRAITEMENT DE L'ACIDÉMIE PROPIONIQUE PROVOQUÉE PAR DES MUTATIONS DE LA PROPIONYL-COA CARBOXYLASE BÊTA | [2022/34] | Entry into regional phase | 26.04.2022 | National basic fee paid | 26.04.2022 | Designation fee(s) paid | 26.04.2022 | Examination fee paid | Examination procedure | 26.04.2022 | Examination requested [2022/34] | 26.04.2022 | Date on which the examining division has become responsible | 05.12.2022 | Amendment by applicant (claims and/or description) | Fees paid | Renewal fee | 27.10.2022 | Renewal fee patent year 03 | 27.10.2023 | Renewal fee patent year 04 |
Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [XY]WO2016168728 (UNIV EMORY [US], et al) [X] 1-3,5-8,10-12,22,29,30,35,38,44,45,47-49 * claims; page 37, lines 24-27; page 39, lines 8-12; * [Y] 1-56; | [XY]WO2019104195 (MODERNATX INC [US]) [X] 1-3,5-7,44,47-49,51-53 * example -; claim -; sequence - * [Y] 1-56; | [XP]WO2020072451 (ULTRAGENYX PHARMACEUTICAL INC [US]) [XP] 1* figures 2, 8-12; examples 5-8; claim - *; | [Y] - CHANDLER R J ET AL, "P331 Liver directed gene therapy using AAV9 to treat a new murine model of propionic acidemia caused by Pccb deficiency", HUMAN GENE THERAPY, (20181101), vol. 27, page A124, XP055770020 [Y] 1-56 * abstract * | [Y] - MOISE-SILVERMAN J ET AL, "423. Systemic AAV Gene Therapy Rescues Murine Models of Propionic Acidemia Caused Mutations in Pccb from Neonatal Lethality", MOLECULAR THERAPY, (20190401), vol. 27, no. 4S1, page 201, XP055770018 [Y] 1-56 * abstract * | [YP] - Chandler R J ET AL, "Mouse Models of, and AAV Gene Therapy for, Propionic Acidemia", 23rd ASGCT Annual Meeting, May 12 - 15, 2020, (20200512), URL: https://cslide-us.ctimeetingtech.com/asgct23/attendee/eposter/file/515#1, (20210128), XP055770005 [YP] 1-56 * abstract, figure 4, figure 5, conclusions; * | [YP] - CHANDLER R J ET AL, "250. Mouse Models of, and AAV Gene Therapy for, Propionic Acidemia", MOLECULAR THERAPY, (20200428), vol. 28, no. 4S1, page 118, XP055770006 [YP] 1-56 * abstract * | by applicant | - CHANDLER et al., Mol Ther, (20100000), vol. 18, pages 11 - 6 |